This clinical trial looks at new ways to treat high-risk, early-stage breast cancer. The focus is on two types: triple-negative breast cancer and hormone receptor-low positive/HER2-negative breast cancer. The main goal is to see if a new medicine, sacituzumab tirumotecan, combined with pembrolizumab and chemotherapy, helps reduce cancer in the body better than chemotherapy alone with pembrolizumab.
This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. The trial plans to include about 2,400 participants. It is regulated by the FDA.
Who can join
This trial is open to men and women aged 18 and older. You can join if you have high-risk, early-stage breast cancer that has not been treated before. You cannot join if you have metastatic breast cancer or have had previous treatments for this cancer.
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into two groups by chance. One group will receive the new treatment, sacituzumab tirumotecan along with pembrolizumab and chemotherapy. The other group will receive standard chemotherapy with pembrolizumab. Everyone will receive treatment for several weeks, followed by surgery. After surgery, additional treatments may be given based on what the doctors recommend.
Where
This trial is enrolling at 57 locations. Recruiting sites are listed first.
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044)
Altamonte Springs, Florida
Recruiting
Altru Health System ( Site 0057)
Grand Forks, North Dakota
Recruiting
Avera Cancer Institute - Yankton ( Site 0089)
Yankton, South Dakota
Recruiting
Avera McKennan Hospital ( Site 0002)
Sioux Falls, South Dakota
Recruiting
Banner MD Anderson Cancer Center ( Site 0066)
Gilbert, Arizona
Recruiting
Bioresearch Partner ( Site 0072)
Hialeah, Florida
Recruiting
Bon Secours Cancer Institute at St. Francis ( Site 0048)
Director of the Breast Cancer Center at NYU Langone’s Perlmutter Cancer Center. Treats breast cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Inaugural Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery, WashU. Treats breast cancer. A surgeon is the doctor who removes cancer with an operation (adults). Recognized at state, national or international level.
Microsurgical breast reconstruction specialist, MSK. Treats breast cancer and mouth cancer. Offers microsurgical breast reconstruction, head and neck reconstruction and abdominal wall reconstruction.